Halozyme, Inc.

Halozyme and Oruka entered a global exclusive collaboration and license agreement for use of Halozyme’s Hypercon™ technology with ORKA‑001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Learn more: ir.halozyme.com/news/news-deta…

Halozyme announced a global exclusive collaboration with Vertex Pharmaceuticals to license its Hypercon™ technology for up to three drug targets. Read more here: ir.halozyme.com/news/news-deta…

Halozyme reported record FY2025 results: • Revenue up 38% to $1.4B • Royalties up 52% to $868M Driven by ENHANZE®, partner launches & our expanded drug delivery portfolio. We’re reiterating strong 2026 guidance ($1.71–$1.81B revenue) with royalties expected to exceed $1B.

Halozyme acquires Surf Bio, raises 2025 revenue estimates and increases 2026 & multi‑year guidance. More here: tinyurl.com/3ybpuk82

Halozyme will host an Investor Conference Call on Jan 28 at 5:30am PT / 8:30am ET. Dr. Helen Torley (CEO) and Nicole LaBrosse (CFO) will share preliminary FY25 revenue results, updated 2026–2028 financial guidance, and a business update. Register: registrations.events/direct/Q4I1205…

We have entered a global collaboration with Takeda to provide access to our drug delivery technology for use with its Crohn’s and ulcerative colitis biologic therapy. Read more: ow.ly/M9sh50XWtQQ #IBD #CrohnsDisease #UlcerativeColitis #DrugDeliveryInnovation

Halozyme and Skye Bioscience announce a global collaboration to evaluate nimacimab co-formulated with ENHANZE® for obesity, supporting higher-dose subcutaneous administration strategies. Details: lnkd.in/gez9Vjf5 #Halozyme #SkyeBioscience #ENHANZE #ObesityResearch

The U.S. FDA has approved @JNJNews new subcutaneously administered therapy for the treatment of EGFR-mutated advanced NSCLC in adults. Co-formulated with our drug delivery technology, it has the potential to offer more personalized care. ow.ly/TqC950XLN6W

Halozyme has completed the acquisition of Elektrofi, adding Hypercon™ ultra-high concentration technology to our drug delivery portfolio. This milestone expands our ability to make treatments fit seamlessly into patients’ lives. Learn more: ow.ly/m9X450XtR4C

Merus and Halozyme have entered a global collaboration to develop a subcutaneous formulation of petosemtamab using Halozyme’s ENHANZE® technology – aiming to improve treatment efficiency and patient experience. Learn more: ow.ly/IxVz50Xte6s #DrugDelivery #Innovation

Halozyme Delivers Strong Q3 2025 Results — Raises Full-Year Guidance We reported another quarter of robust growth, view the full press release here: ow.ly/x2Kz50XmGfo #Halozyme #Q3Results #InvestorRelations #Biotech #FinancialPerformance #Growth

One week to go! We’re headed to #PDAUniverse in Vienna, Oct 21–22 — find us at Booth 18 or presenting! Explore our portfolio of auto-injectors, including the HVAI™ — designed for subcutaneous delivery of large-volume biologics. Want to meet? Drop us a comment!

We’re heading to Fierce Biotech Week! Dr. Helen Torley, CEO & President Oct 7 | 3:45–4:15 PM "The Future, Under Your Skin – Why Subcutaneous Tech is the Next Frontier in Medicine” Dr. Charles Theuer, CMO Oct 8 | 2:45–3:30 PM "Formulation & Innovation for Next-Gen Therapies"

We kicked off our annual #StJude fundraiser with a picnic and a bold goal: 25M steps $25K raised We’re proud to support St. Jude Children's Research Hospital, where families never receive a bill for care. Follow our journey as we walk, run & roll together! #OneTeam

New publication in the Journal of Controlled Release: "An industry perspective on clinical development and regulatory strategies for subcutaneously administered high-dose biologics" Co-authored by Halozyme and peers from the SC Drug Delivery Consortium. ow.ly/TNIi50WXM9X

Our VP of Corporate Communications & IR will be hosting 1x1 investor meetings tomorrow at the H.C. Wainwright 27th Annual Global Investment Conference in NYC. Sept 9, 2025 1x1 Meetings New York, NY #InvestorRelations #HCWainwright #IR #NYC

Our CEO, Dr. Helen Torley, will join the Morgan Stanley 23rd Annual Global Healthcare Conference for a fireside chat + 1x1 investor meetings. Sept 8, 2025 4:45am PT / 7:45am ET NYC Webcast: ow.ly/Ae9E50WSfVk #HALO #Biotech #HealthcareLeadership #InvestorRelations

We’re excited to share that our President & CEO, Dr. Helen Torley, will join the 2025 Wells Fargo Healthcare Conference this week in Boston! Sept 4 | 10:30am PT / 1:30pm ET Fireside Chat + 1x1 Investor Meetings Learn more: ow.ly/G8rB50WPZnO

One Team, Big Impact! Our 2025 Dedicated Service Time brought employees together to support 8 incredible orgs - packing meals, making blankets, clearing trails & more. Thank you to everyone who gave their time & heart! #OneTeam #CommunityImpact #Volunteering #MakingADifference

New research alert! Our experts co-authored a study on a rapid high-volume AI (HVAI) that can deliver 10 mL in 30 s to administer therapeutics co-formulated with a proprietary recombinant human hyaluronidase PH20 (rHuPH20). doi.org/10.1007/s13346… #DrugDelivery #Biotech